BMS and Alder's IL-6 blocker positive in Phase II RA study
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Alder Biopharmaceuticals' monoclonal antibody against interleukin-6 (IL-6), BMS-945429 (also known as ALD518), has met the primary endpoint of a Phase IIa study in rheumatoid arthritis, the companies have said.